^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Is antiangiogenic therapy necessary for patients with metastatic colorectal cancer (mCRC) and mutation in the BRAF gene? Results of the systematic review and meta-analysis
Published date:
01/11/2021
Excerpt:
...compared chemotherapy (CT) plus bevacizumab or aflibercept or ramucirumab and CT alone at the first-line or second-lines with information of the BRAF status... a tendency for significant improvement in PFS (HR 0.64, 95% CI 0.4-1.02; p = 0.06; I2 = 0%, p for heterogeneity 0.7; 53trials) and significant improvement in OS (HR 0.51, 95% CI 0.32-0.82; p = 0.005; I2 = 0%, p for heterogeneity 0.52; 4 trials) in group of ani-angiogenic therapy. Addition of anti-angiogenic therapy to chemotherapy showed improvement in the PFS and OS in pts with mBRAF compared with chemotherapy alone.
Secondary therapy:
Chemotherapy
Trial ID:
Source:
Title:
Real-world study of the efficacy and safety of bevacizumab for first-line and post-first-line treatment of advanced RAS mutated colorectal cancer
Excerpt:
...6.RAS mutation, regardless of BRAF. ...
Trial ID:
Source:
Title:
CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC
Excerpt:
...Ras/Braf mutation analysis at enrollment identifies Ras/Braf status as either the wild type or mutant type....
Trial ID:
More C2 evidence
Source:
Title:
Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP)
Excerpt:
...CTP as predictive marker for efficacy measured by progression-free survival`CTP as predictive marker for efficacy measured by overall survival`Tumor vasculature at progression`Subgroup analyses according to the RAS mutation status, BRAF mutation status and VEGF-A level`Local and distant recurrences...
Trial ID:
Source:
Title:
Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells
Excerpt:
...Overall survival (OS)`Response rate (RR)`Radical Resection (R0) surgery rate`Circulating Tumour Cells (CTC) count basal and correlate to PFS, OS, RR`Correlation of RAS, BRAF and PI3K mutations and clinical anti-tumour activity outcome ( PFS, OS, RR)`Adverse events`Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR)...
Trial ID:
Source:
Title:
Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy
Excerpt:
...An ARMS-PCR proven KRAS, NRAS mutation, excluding BRAF mutation or microsatellite instablility-High; 3....
Trial ID:
Source:
Title:
Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer
Excerpt:
...RAS/BRAF mutation status and UGT1A1*28/*6 gene polymorphism typing should be determined before enrollment....
Trial ID:
Less C2 evidence
Source:
Title:
Metastatic colorectal cancer in both sides of Aegean Sea: practice patterns and outcome
Published date:
02/03/2022
Excerpt:
RAS and BRAF mutation rates were found to be 36% and 39%, respectively. As first-line therapy, 196 (54%) patients received bevacizumab and Anti-EGFR treatments in combination with chemotherapy….Objective response rate was 42% (n = 152) and 32% (n = 78) for 1st line and 2nd line treatments, respectively. While the median progression free survival (PFS) with the 1st line treatment was 10 months, it was 7 months with the 2nd line treatments. In the total study population median PFS and overall survival (OS) were 10 (95% CI, 8.3 - 11.6) and 35 (95% CI, 30.7 - 39.2) months, respectively....it was found that wild RAS and BRAF mutations and second metastasectomy contributed to overall survival (p = 0.047 and p < 0.001).
Secondary therapy:
Chemotherapy + THE-349
DOI:
https://doi.org/10.1080/03007995.2022.2037848
Source:
Title:
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial
Excerpt:
Between May 2012 and March 2015, 232 patients, mostly with RAS (65%) or BRAF (9%) mutant tumours, were randomised in 16 Italian centres....The activity of FOLFOXIRI plus bevacizumab is confirmed in a population with high prevalence of RAS/BRAF mutations treated with a 4 months induction.
Secondary therapy:
FOLFOXIRI
DOI:
10.1016/j.ejca.2018.12.028
Trial ID:
